Genta has said it has completed its response to outstanding issues the European Medicines Agency highlighted regarding its marketing application for Genasense, an anticancer product for advanced melanoma.
Subscribe to our email newsletter
The company now anticipates that agency will complete its review and issue its opinion regarding approval within the next 90 days.
Genasense is a novel targeted therapy that blocks the production of Bcl-2, a protein that appears to be a fundamental cause of resistance to cancer treatment. By knocking down Bcl-2 in cancer cells, Genasense may enhance the effectiveness of chemotherapy in patients with advanced melanoma.
According to Genta, the application is based on long-term data derived from the largest randomized controlled trial that has ever been conducted in patients with advanced melanoma.